Belgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.

The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.

Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.

Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.